Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

Charles A. Kunos; Denise Fabian; Dava W. Piecoro; Dana Napier; Rachel W. Miller; Frederick R. Ueland

doi:10.3389/fonc.2023.948348

Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

Charles A. Kunos, Denise Fabian, Dava W. Piecoro, Dana Napier, Rachel W. Miller, Frederick R. Ueland

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.

Original language	English
Article number	948348
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.948348
State	Published - Jan 24 2023

Bibliographical note

Funding Information:
This research was supported by an NCI grant (P30 CA177558) which supports the Biospecimen Procurement & Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center.

Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland.

Keywords

HER2/neu
radiopharmaceutical
triage
uterine cervical adenocarcinoma
uterine cervical cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2023.948348

Cite this

@article{ecb4ba8e2b8a486c85ecefa64938d2d3,

title = "Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky",

abstract = "Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.",

keywords = "HER2/neu, radiopharmaceutical, triage, uterine cervical adenocarcinoma, uterine cervical cancer",

author = "Kunos, {Charles A.} and Denise Fabian and Piecoro, {Dava W.} and Dana Napier and Miller, {Rachel W.} and Ueland, {Frederick R.}",

note = "Funding Information: This research was supported by an NCI grant (P30 CA177558) which supports the Biospecimen Procurement & Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center. Publisher Copyright: Copyright {\textcopyright} 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland.",

year = "2023",

month = jan,

day = "24",

doi = "10.3389/fonc.2023.948348",

language = "English",

volume = "13",

}

TY - JOUR

T1 - Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

AU - Kunos, Charles A.

AU - Fabian, Denise

AU - Piecoro, Dava W.

AU - Napier, Dana

AU - Miller, Rachel W.

AU - Ueland, Frederick R.

N1 - Funding Information: This research was supported by an NCI grant (P30 CA177558) which supports the Biospecimen Procurement & Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center. Publisher Copyright: Copyright © 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland.

PY - 2023/1/24

Y1 - 2023/1/24

N2 - Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.

AB - Introduction: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. Methods: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. Results: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. Discussion: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.

KW - HER2/neu

KW - radiopharmaceutical

KW - triage

KW - uterine cervical adenocarcinoma

KW - uterine cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=85147442344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147442344&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.948348

DO - 10.3389/fonc.2023.948348

M3 - Article

AN - SCOPUS:85147442344

VL - 13

M1 - 948348

ER -

Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this